Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors

While type 2 diabetes (T2D) is commonly seen in primary care, it is difficult to manage successfully over time. This series offers brief eNewsletters written by clinical experts that are designed to assist in the clinical management of patients with T2D.

This third eNewsletter in the series, entitled, Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors, was written by Matthew L. Mintz, MD. It explores how the kidney helps to maintain glucose homeostasis and how dysfunctional glucose reabsorption by the sodium-glucose cotransporter-2 (SGLT-2) contributes to the pathophysiology of T2D. The effect of SGLT-2 inhibitors on glycemic control, body weight, blood pressure, and uric acid levels in patients with T2D are also discussed.

Click here to read the supplement

While type 2 diabetes (T2D) is commonly seen in primary care, it is difficult to manage successfully over time. This series offers brief eNewsletters written by clinical experts that are designed to assist in the clinical management of patients with T2D.

This third eNewsletter in the series, entitled, Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors, was written by Matthew L. Mintz, MD. It explores how the kidney helps to maintain glucose homeostasis and how dysfunctional glucose reabsorption by the sodium-glucose cotransporter-2 (SGLT-2) contributes to the pathophysiology of T2D. The effect of SGLT-2 inhibitors on glycemic control, body weight, blood pressure, and uric acid levels in patients with T2D are also discussed.

Click here to read the supplement

While type 2 diabetes (T2D) is commonly seen in primary care, it is difficult to manage successfully over time. This series offers brief eNewsletters written by clinical experts that are designed to assist in the clinical management of patients with T2D.

This third eNewsletter in the series, entitled, Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors, was written by Matthew L. Mintz, MD. It explores how the kidney helps to maintain glucose homeostasis and how dysfunctional glucose reabsorption by the sodium-glucose cotransporter-2 (SGLT-2) contributes to the pathophysiology of T2D. The effect of SGLT-2 inhibitors on glycemic control, body weight, blood pressure, and uric acid levels in patients with T2D are also discussed.

Click here to read the supplement